PFG Investments LLC Has $13.55 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

PFG Investments LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 93,713 shares of the company's stock after selling 1,853 shares during the quarter. Johnson & Johnson comprises about 0.8% of PFG Investments LLC's investment portfolio, making the stock its 14th largest holding. PFG Investments LLC's holdings in Johnson & Johnson were worth $13,553,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Vinva Investment Management Ltd boosted its stake in Johnson & Johnson by 6.8% in the 3rd quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company's stock worth $17,988,000 after purchasing an additional 7,110 shares during the period. Financial Counselors Inc. grew its stake in Johnson & Johnson by 5.3% during the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company's stock valued at $29,996,000 after acquiring an additional 9,309 shares in the last quarter. Meridian Investment Counsel Inc. increased its holdings in shares of Johnson & Johnson by 19.6% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company's stock valued at $3,667,000 after purchasing an additional 3,710 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company's stock worth $2,858,543,000 after purchasing an additional 102,502 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new position in Johnson & Johnson during the third quarter valued at approximately $69,859,000. Institutional investors own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ stock traded up $1.72 during midday trading on Thursday, reaching $152.87. 2,045,698 shares of the company's stock traded hands, compared to its average volume of 9,333,421. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a 50-day simple moving average of $147.73 and a two-hundred day simple moving average of $156.10. The company has a market cap of $368.05 billion, a price-to-earnings ratio of 22.98, a PEG ratio of 2.45 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 EPS. On average, analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. Johnson & Johnson's payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a report on Thursday, January 23rd. Bank of America cut their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, January 23rd. Guggenheim upped their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $170.44.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.